Proteome Sciences plc

Proteome Sciences plc, established in 1993 and based in Cobham, United Kingdom, specializes in delivering contract research services. The company's core expertise lies in the identification, validation, and practical application of protein biomarkers for clients across the United States, the United Kingdom, and the European Union. Its extensive portfolio includes a range of sophisticated proteomic solutions: SysQuant offers comprehensive insights into protein activity within regulatory and signaling pathways. For analyzing cells and tissues without the need for phosphopeptide enrichment, they provide TMT MS2. TMT MS3 is a critical method for biomarker discovery in complex samples, such as plasma, where precise quantification is paramount. The TMT Calibrator enables simultaneous analysis of diseased or treated tissue alongside peripheral fluids. Rapid validation of biomarker candidates is facilitated by TMT SRM, a targeted assay format. Additionally, the company performs SRM assays, a targeted mass spectrometry technique for routine biomarker measurement. Complementing these laboratory services, Proteome Sciences also offers a suite of bioinformatics tools. These include: Proteome Discoverer, utilized for peptide sequencing and TMT quantification. SQuaT, CalDIT, and DIANA, which normalize quantitative data and provide functional annotation for peptides and proteins. FeaST, a visualization tool for assessing data quality, building class identifier models, and generating biomarker candidate lists. FAT, designed to identify variations in biological processes and cellular components. The company's primary clientele comprises pharmaceutical and biotechnology firms, as well as academic research institutions.

Proteome Sciences plc trades as PRM.L on LSE. The company is classified in Healthcare / Medical - Diagnostics & Research and reports in GBP.

The current profile places the business in Medical - Diagnostics & Research. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows £3.76M of revenue and -£3.06M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Proteome Sciences plc can be compared against peers such as ANGLE plc, Chill Brands Group PLC, CRISM Therapeutics Corporation, Feedback plc, Genedrive Plc, MyHealthChecked PLC.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of £4.48M, beta of 0.17, and return on equity of +32.1%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

PRM.L currently shows total debt of £15.77M and beta of 0.17. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.proteomics.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.